Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

0.92 -2.13

Buy Sell

Overview

Share price change

24h

Current

Min

0.92

Max

0.94

Key metrics
By Trading Economics
Income	418K -5.5M
EPS	-0.18
Profit margin	-6,600
Employees	25
EBITDA	906K -5.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+330.11% upside

Dividends
By Acuity
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-7.5M 30M
Previous open	3.05
Previous close	0.92

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jul 2026, 23:51 UTC

Cryptocurrency declines amid cautious investor sentiment ahead of key inflation data and geopolitical tensions impacting U.S. markets.

11 Jul 2026, 23:51 UTC

Cryptocurrency prices dip amid geopolitical tensions and cautious investor sentiment ahead of key U.S. inflation reports.

11 Jul 2026, 23:51 UTC

U.S. Stocks Rise Amid AI Enthusiasm and Geopolitical Tensions; Key Inflation Data and China's Declining Retail Sales Loom Ahead.

11 Jul 2026, 23:51 UTC

Cryptocurrency market dips as Bitcoin and Ethereum decline, while U.S. stocks rise ahead of key inflation data and China's retail sales forecast shows potential consumer spending weakness.

11 Jul 2026, 23:51 UTC

Mixed sentiment ahead of NAB Business Confidence report release on July 14, amid ongoing economic concerns and geopolitical uncertainties in Australia.

11 Jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is lower during Saturday's session, continuing a decline since Friday's close. Volatility included a session high earlier before pulling back.

11 Jul 2026, 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Weakening Consumer Spending and Economic Uncertainty

11 Jul 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on July 16, 2026, Amid Cautious Market Sentiment Due to Geopolitical Tensions and Upcoming Economic Data.

11 Jul 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Strong Consumer Spending Trends, According to Bank of America Report

11 Jul 2026, 23:31 UTC

Canada's Housing Starts Data for June 2026 Expected at 260K Amid Economic Volatility and Affordability Concerns.

11 Jul 2026, 23:21 UTC

U.S. Core Producer Prices Expected to Rise 0.4% in June Amid Mixed Global Inflation Signals and Economic Uncertainties

11 Jul 2026, 23:21 UTC

Cautious Market Sentiment Ahead of July 15 Release of NY Empire State Manufacturing Index Amid Geopolitical Tensions and Earnings Reports

11 Jul 2026, 23:21 UTC

Producers Price Inflation (PPI) MoM for June 2026 set to release on July 15, with a forecasted increase of 0.2%, influencing potential Federal Reserve interest rate decisions amid ongoing inflation concerns.

11 Jul 2026, 23:11 UTC

Brazil's Retail Sales Report on July 16, 2026, Expected to Show Volatility Amid Economic Uncertainty and Mixed Previous Results.

11 Jul 2026, 23:01 UTC

Investors Cautiously Await U.S. Core Inflation Rate Release Amid Geopolitical Tensions and Earnings Uncertainty

11 Jul 2026, 23:01 UTC

Upcoming U.S. CPI Release on July 14 Sparks Caution Among Investors Amid Inflation Concerns and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

Investors Brace for July 14 CPI Release Amid High Inflation Concerns and Potential Fed Rate Hike

11 Jul 2026, 23:01 UTC

Investors Brace for July CPI Release Amid Inflation Concerns and Market Volatility

11 Jul 2026, 23:01 UTC

US Core Inflation Rate Expected to Rise 0.3% in June Amid Market Caution and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

U.S. Inflation Rate Expected to Decrease Slightly in June Amid Cautious Market Sentiment and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

Correlated Moves

The Dow Jones Index declined during after-market hours, reflecting cumulative weakness since Friday's close amid broader market sentiment.

11 Jul 2026, 22:53 UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid optimistic market sentiment following positive employment figures and easing geopolitical tensions.

11 Jul 2026, 22:53 UTC

Australia's Westpac Consumer Confidence report on July 14, 2026, is expected to show improvement amid positive stock market gains and ongoing inflation concerns.

11 Jul 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on July 15 Expected to Reflect Ongoing Inflation and Geopolitical Tensions Impacting Market Sentiment.

11 Jul 2026, 22:31 UTC

Brazil's Central Bank to Provide Key Interest Rate Outlook on July 13, Amid Global Inflationary Trends.

11 Jul 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline by 4.2% in May Amid Mixed Economic Sentiment and Geopolitical Tensions

11 Jul 2026, 22:21 UTC

Singapore's Upcoming GDP Growth Rate Release Sparks Cautious Optimism Amid Regional Market Trends and Global Economic Factors

11 Jul 2026, 21:41 UTC

South Korea's Unemployment Rate Release on July 14 Expected to Show Increase Amid Economic Concerns and Job Losses.

11 Jul 2026, 21:31 UTC

UK Retail Sales Monitor YoY Forecasts 2.9% Growth Amid Mixed Sentiment and Geopolitical Concerns Ahead of July Release

11 Jul 2026, 20:41 UTC

India's June 2026 Inflation Rate Expected at 4.3%, Amid Rising Prices and Geopolitical Concerns

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

330.11% upside

12 Months Forecast

Average 4 USD 330.11%

High 4 USD

Low 4 USD

Based on 1 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.